| Title | A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) |
|---|---|
| Disease/Condition | Kidney Diseases (incl Chronic Kidney Disease),Kidney Cancer,Oncology (Medical/Hematologic),Urologic Oncology (Med Onc),Carcinoma,Urogenital Neoplasms |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | Benjamin Gartrell, MD |
| Contact Name | Gina Aracena |
| Contact Email | gihernan@montefiore.org |
| IRB/Protocol Number | 2017-7787 |
| Status | Active/Enrolling |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |